tradingkey.logo
搜索

Eton Pharmaceuticals Inc

ETON
添加自选
37.225USD
+0.595+1.62%
收盘 07/02, 13:00美东报价延迟15分钟
1.02B总市值
亏损市盈率 TTM

Eton Pharmaceuticals Inc

37.225
+0.595+1.62%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.62%

5天

+9.55%

1月

+29.79%

6月

+120.14%

今年开始到现在

+120.14%

1年

+165.70%

关键数据
36.940今开
37.425最高
356.52K成交量
亏损市盈率 TTM
19.91市盈率动
--股息TTM
1.30%换手率
36.630昨收
36.630最低
9.61M成交额
亏损市盈率静
33.27市净率
0.00%股息率 TTM
-1.62%ROA
35.66052周最高
1.11量比
-3.82M净利润
27.36M总股本
-0.0556每股收益TTM
0.88Beta
-5.36%ROE
13.08552周最低
2.17%振幅
60.72%毛利率
1.02B总市值
10.78回报/风险
3.12%风险率

TradingKey Eton Pharmaceuticals Inc股票评分

单位: USD 更新时间: 2026-07-01

操作建议

Eton Pharmaceuticals Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名45/157位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价45.67。中期看,股价处于上升通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Eton Pharmaceuticals Inc评分

相关信息

行业排名
45 / 157
全市场排名
114 / 4564
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Eton Pharmaceuticals Inc亮点

亮点风险
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
业绩高增长
公司营业收入稳步增长,连续3年增长152.67%
业绩增长期
公司处于发展阶段,最新年度总收入79.95M美元
利润高增长
公司净利润处于行业前列,最新年度总收入79.95M美元
估值低估
公司最新PE估值-659.17,处于3年历史低位
机构减仓
最新机构持股15.99M股,环比减少18.71%
ETHSX持仓
明星投资者ETHSX持仓,最新持仓市值15.71K

分析师目标

根据 3 位分析师
买入
评级
45.667
目标均价
+26.15%
涨幅空间

Eton Pharmaceuticals Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Eton Pharmaceuticals Inc简介

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代码ETON
公司Eton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
网址https://etonpharma.com/

常见问题

Eton Pharmaceuticals Inc(ETON)的当前股价是多少?

Eton Pharmaceuticals Inc(ETON)的当前股价是 36.63。

Eton Pharmaceuticals Inc的股票代码是什么?

Eton Pharmaceuticals Inc的股票代码是ETON。

Eton Pharmaceuticals Inc股票的52周最高点是多少?

Eton Pharmaceuticals Inc股票的52周最高点是35.66。

Eton Pharmaceuticals Inc股票的52周最低点是多少?

Eton Pharmaceuticals Inc股票的52周最低点是13.09。

Eton Pharmaceuticals Inc的市值是多少?

Eton Pharmaceuticals Inc的市值是1.00B。

现在Eton Pharmaceuticals Inc(ETON)的股票是买入、持有还是卖出?

根据分析师评级,Eton Pharmaceuticals Inc(ETON)的总体评级为买入,目标价格为45.67。

Eton Pharmaceuticals Inc(ETON)股票的每股收益(EPS TTM)是多少

Eton Pharmaceuticals Inc(ETON)股票的每股收益(EPS TTM)是-0.17。